Neulasta

Latest stories

5d
The Economic Times
Novartis aims to nearly triple biosimilar drugs on market by 2020expire. Sandoz head Richard Francis said his versions of AbbVie's $13 billion
Novartis aims to nearly triple biosimilar drugs on market by 2020
The Economic Times / Posted 5 days ago
expire. Sandoz head Richard Francis said his versions of AbbVie's $13 billion blockbuster Humira, Amgen's Enbrel and Neulasta, Johnson & Johnson's Remicade and Roche's Rituxan would arrive in pharmacies over the next four years, barring... Read more
2 related stories
6d
The Financial Express
Switzerland Novartis aims to nearly triple biosimilar drugs on market by 2020drugs expire. Sandoz head Richard Francis said his versions of AbbVie’s $13 bi
Switzerland Novartis aims to nearly triple biosimilar drugs on market by 2020
The Financial Express / Posted 6 days ago
drugs expire. Sandoz head Richard Francis said his versions of AbbVie’s $13 billion blockbuster Humira, Amgen’s Enbrel and Neulasta, Johnson & Johnson’s Remicade and Roche’s Rituxan would arrive in pharmacies over the next four years, barring... Read more
2 related stories
6d
Providence Business News
Purposeful engagement around a noble cause2016 Q1, propelled in part by Enbrel; Prolia, which treats postmenopausal osteo
Purposeful engagement around a noble cause
Providence Business News / Posted 6 days ago
2016 Q1, propelled in part by Enbrel; Prolia, which treats postmenopausal osteoporosis; bone-marrow stimulant Aranesp; and Neulasta, which is used to decrease infection risk. Producing products that positively impact people "definitely does... Read more
6d
Channel NewsAsia
Novartis aims to nearly triple biosimilar drugs on market by 2020expire. Sandoz head Richard Francis said his versions of AbbVie's US$13 billio
Novartis aims to nearly triple biosimilar drugs on market by 2020
Channel NewsAsia / Posted 6 days ago
expire. Sandoz head Richard Francis said his versions of AbbVie's US$13 billion blockbuster Humira, Amgen's Enbrel and Neulasta, Johnson & Johnson's Remicade and Roche's Rituxan would arrive in pharmacies over the next four years, barring... Read more
2 related stories
7d
FOX Business
2 Biotech Stocks That Could Raise Their Dividends -- and 1 That Won't2013, but competition from a biosimilar for Neupogen and a generic version of E
2 Biotech Stocks That Could Raise Their Dividends -- and 1 That Won't
FOX Business / Posted 7 days ago
2013, but competition from a biosimilar for Neupogen and a generic version of Epogen is now inflicting damage. Cancer drug Neulasta's U.S. patent expired last year. Amgen reported a 4% year-over-year sales increase for Neulasta in the first... Read more
7d
FOX Business
2 Biotech Stocks That Could Raise Their Dividends -- and 1 That Won't2013, but competition from a biosimilar for Neupogen and a generic version of E
2 Biotech Stocks That Could Raise Their Dividends -- and 1 That Won't
FOX Business / Posted 7 days ago
2013, but competition from a biosimilar for Neupogen and a generic version of Epogen is now inflicting damage. Cancer drug Neulasta's U.S. patent expired last year. Amgen reported a 4% year-over-year sales increase for Neulasta in the first... Read more
21d
FOX Business
The New $17 Billion Market You've Probably Never Heard of (and 3 Stocks Poised to Profit)wonder.Playing both sides Not only is Amgen's Enbrel under biosimilar threat f
The New $17 Billion Market You've Probably Never Heard of (and 3 Stocks Poised to Profit)
FOX Business / Posted 21 days ago
wonder.Playing both sides Not only is Amgen's Enbrel under biosimilar threat from Biogen and Samsung's Benepali, but its Neulasta is also being targeted by Novartis'Zarxio -- the first biosimilar approved in the United States. Recognizing that... Read more
3 related stories
21d
FOX Business
The New $17 Billion Market You've Probably Never Heard of (and 3 Stocks Poised to Profit)wonder.Playing both sides Not only is Amgen's Enbrel under biosimilar threat f
The New $17 Billion Market You've Probably Never Heard of (and 3 Stocks Poised to Profit)
FOX Business / Posted 21 days ago
wonder.Playing both sides Not only is Amgen's Enbrel under biosimilar threat from Biogen and Samsung's Benepali, but its Neulasta is also being targeted by Novartis'Zarxio -- the first biosimilar approved in the United States. Recognizing that... Read more
3 related stories

People in this news